文献速递脑血管病

利伐沙班与阿司匹林在ESUS合并颈动脉粥样硬化中的疗效与安全性

Efficacy and Safety of Rivaroxaban Versus Aspirin in Embolic Stroke of Undetermined Source and Carotid Atherosclerosis.
PubMed 文献 · Stroke · 2019-08-12

NAVIGATE-ESUS试验的探索性亚组分析,评估合并颈动脉粥样硬化的ESUS患者中利伐沙班与阿司匹林的疗效和安全性。结果显示两组缺血性卒中复发率无显著差异,但利伐沙班大出血风险更高;颈动脉斑块在同侧卒中更常见,支持非狭窄性颈动脉病变的病因作用。

要点

  • 合并颈动脉狭窄或斑块的ESUS患者中,利伐沙班与阿司匹林预防卒中复发疗效无显著差异。
  • 颈动脉斑块患者中利伐沙班大出血风险显著高于阿司匹林。
  • 颈动脉斑块更多见于同侧卒中,提示非狭窄性颈动脉病变的病因作用。

核心结论

  • 在合并颈动脉粥样硬化的ESUS患者中,利伐沙班与阿司匹林预防卒中复发疗效无差异,但阿司匹林更安全,与总体试验结果一致。

研究设计与样本

  • NAVIGATE-ESUS试验的探索性亚组分析,评估合并颈动脉粥样硬化(轻度狭窄20%-49%或斑块)的ESUS患者。

主要发现

  • 颈动脉斑块存在于40%的参与者,轻度颈动脉狭窄存在于11%。
  • 490例颈动脉狭窄患者中,利伐沙班组与阿司匹林组缺血性卒中复发率分别为5.0 vs 5.9/100患者年(HR 0.85,95%CI 0.39-1.87;与无狭窄患者的交互作用P=0.78)。
  • 2905例颈动脉斑块患者中,利伐沙班组与阿司匹林组缺血性卒中复发率分别为5.9 vs 4.9/100患者年(HR 1.20,95%CI 0.86-1.68;交互作用P=0.2)。
  • 颈动脉斑块患者中,利伐沙班组大出血发生率高于阿司匹林组(2.0 vs 0.5/100患者年,HR 3.75,95%CI 1.63-8.65)。
  • 颈动脉狭窄患者与无狭窄者缺血性卒中复发率相似(5.4 vs 4.9/100患者年,HR 1.11,95%CI 0.73-1.69);颈动脉斑块患者复发率有高于无斑块者的趋势(5.4 vs 4.3/100患者年,HR 1.23,95%CI 0.99-1.54)。

临床怎么用

  • 对于合并颈动脉粥样硬化的ESUS患者,选择抗栓方案时需权衡疗效与出血风险,阿司匹林可能更安全。
  • 颈动脉斑块的存在应引起对同侧栓塞来源的重视,即使狭窄程度不重。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background and Purpose- The sources of emboli in patients with embolic stroke of undetermined source (ESUS) are multiple and may not respond uniformly to anticoagulation. In this exploratory subgroup analysis of patients with carotid atherosclerosis in the NAVIGATE (New Approach Rivaroxaban Inhibition of Factor Xa in a Global Trial Versus ASA to Prevent Embolism)-ESUS trial, we assessed whether the treatment effect in this subgroup is consistent with the overall trial population and investigated the association of carotid atherosclerosis with recurrent ischemic stroke. Methods- Carotid atherosclerosis was analyzed either as the presence of mild (ie, 20%-49%) atherosclerotic stenosis or, separately, as the presence of carotid plaque. Primary efficacy outcome was ischemic stroke recurrence. Safety outcomes were major bleeding and symptomatic intracerebral bleeding. Results- Carotid plaque was present in 40% of participants and mild carotid stenosis in 11%. There was no significant difference in ischemic stroke recurrence between rivaroxaban- and aspirin-treated patients among 490 patients with carotid stenosis (5.0 versus 5.9/100 patient-years, respectively, hazard ratio [HR], 0.85; 95% CI, 0.39-1.87; P for interaction of treatment effect with patients without carotid stenosis 0.78) and among 2905 patients with carotid plaques (5.9 versus 4.9/100 patient-years, respectively, HR, 1.20; 95% CI, 0.86-1.68; P for interaction of treatment effect with patients without carotid stenosis 0.2). Among patients with carotid plaque, major bleeding was more frequent in rivaroxaban-treated patients compared with aspirin-treated (2.0 versus 0.5/100 patient-years, HR, 3.75; 95% CI, 1.63-8.65). Patients with carotid stenosis had similar rate of ischemic stroke recurrence compared with those without (5.4 versus 4.9/100 patient-years, respectively, HR, 1.11; 95% CI, 0.73-1.69), but there was a strong trend of higher rate of ischemic stroke recurrence in patients with carotid plaque compared with those without (5.4 versus 4.3/100 patient-years, respectively, HR, 1.23; 95% CI, 0.99-1.54). Conclusions- In ESUS patients with carotid atherosclerosis, we found no difference in efficacy between rivaroxaban and aspirin for prevention of recurrent stroke, but aspirin was safer, consistent with the overall trial results. Carotid plaque was much more often present ipsilateral to the qualifying ischemic stroke than contralateral, supporting an important etiological role of nonstenotic carotid disease in ESUS. Clinical Trial Registration- URL: https://www.clinicaltrials.gov. Unique identifier: NCT02313909.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Ntaios G, Swaminathan B, Berkowitz SD, et al. Efficacy and Safety of Rivaroxaban Versus Aspirin in Embolic Stroke of Undetermined Source and Carotid Atherosclerosis. Stroke. 2019. PMID: 31401971. doi:10.1161/STROKEAHA.119.025168

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。